Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. - Wikidata - awgldk - TriplyDB

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

http://www.wikidata.org/entity/Q47871792

about

Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Dapagliflozin efficacy and safety: a perspective review.Dapagliflozin Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes Dapagliflozin for the treatment of type 2 diabetes: a review of the literature Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents Dapagliflozin in patients with type 2 diabetes mellitus.The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation.Dapagliflozin: a review of its use in patients with type 2 diabetes.Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.Pharmacologic treatment of type 2 diabetes: oral medications.Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options

P2860

Q26752815-90C9ED2B-1618-4368-80B6-843875FCF8FB Q26767260-B18FA808-8B4D-4609-8550-C546B97B99F7 Q26767263-3A1010E7-1EEB-4B8A-B118-ABB0DDCBBCEE Q26782225-E0A08F3B-E081-4C8D-876B-423650EA0E44 Q26864336-04FDD517-3A92-4F68-B459-567512A0ED6B Q28072765-34767CE8-E823-4160-A821-FAC40C743360 Q28553482-EB7D3AC4-ED13-4B42-BD52-1F1531653EF6 Q30248634-CE487A30-38D2-4FB9-B2FF-98348AC00671 Q33625207-AB6A246D-26DF-4DA4-8691-F2C760BDD41C Q34161881-3A20CADA-8642-4D81-B85B-4405965430DC Q34198692-3C91C073-307B-4A76-A69C-4018A9E6B237 Q34460468-2C4E93AF-4A39-4593-ADE4-D0CE59422D00 Q34503796-4A426A1F-658C-4CB5-8575-886A0906C563 Q34514280-F7CE67B8-38B6-43FB-A647-3A72645FDE6E Q34613015-2201736D-2191-4B5C-A997-3D8F45087027 Q34699217-E68D5FB4-B458-4BC9-AC24-F7B25FA12989 Q34710819-5294797B-A08C-46F8-A1F6-C407207642B5 Q34726376-6937820F-F0BE-426D-9D1C-7A958033FA99 Q34973750-EBA8FC61-37FF-4535-88F5-05B6A05CE99B Q35064363-54E2BDE9-D43F-4443-888D-F200B1DC6E94 Q35141884-2D67B41F-83A1-4D94-969B-56465AD1F37E Q35260544-42094421-1849-4933-864E-1CC5C3FF03D1 Q35528766-A40E5A00-024C-49AE-99D0-51BFF8C1112A Q35780861-9B0CAD42-1BE3-47BF-A8F7-C2EC4EAC5521 Q36303346-CF9A2D72-C63C-4CBB-A486-3E55AD126672 Q36429733-424EA7B1-D1CC-4A98-8B07-88307D92DC50 Q36599869-D6CCE513-81AC-4292-90EE-1B9CCDD3DDF7 Q37018165-A67658C3-AB47-4C1B-8568-AEDBF40F6611 Q37060860-5D5DAA3A-EF81-4DB3-A80F-605EB414C538 Q37279276-CF8D308F-75E5-428F-950E-C95AD81AEE9B Q37310483-FC6F1BFA-6D4B-4FD5-8AFC-32934375ADE1 Q37427304-EE70BB5C-7BAB-4173-9430-C4B1320151A1 Q37468412-D1745D7B-D95F-4C70-8C2B-465A723BFB6A Q37652799-D9D8960A-A385-47BE-A17B-CB7EF191D48B Q38215995-27C3280F-7C65-44EB-BF62-EA9125EE132D Q38267346-7F292380-1CA1-4DF9-B635-B9C53124E86A Q38270203-7DDB5B72-E707-4782-8BA9-9B24CF88A2BA Q38350347-33BDB284-39CA-41D4-9881-200938604710 Q38386194-49EE098B-7630-4667-8BD5-5CAFA8032E98 Q38452883-52BDA385-94DF-4F11-A084-317742810BC4

P2860

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

http://www.wikidata.org/entity/Q47871792

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Dapagliflozin in patients with ...... icacy and safety over 2 years.

@en

Dapagliflozin in patients with ...... icacy and safety over 2 years.

@nl

type

label

Dapagliflozin in patients with ...... icacy and safety over 2 years.

@en

Dapagliflozin in patients with ...... icacy and safety over 2 years.

@nl

prefLabel

Dapagliflozin in patients with ...... icacy and safety over 2 years.

@en

Dapagliflozin in patients with ...... icacy and safety over 2 years.

@nl

P1433

Q47871792-8A26D676-CC03-4C8F-8F6E-3BBAC5C98AAB

P1476

Q47871792-5633F290-4CCA-423D-AE53-8C9FFD064AF9

P2093

Q47871792-56FE6196-C7B7-48E1-BD18-D0960CC35297

Q47871792-6780E300-3868-4254-A3D5-7FFE4D4F76B6

Q47871792-7BF976BE-B9D3-45CB-9693-3C5D31EF31F5

Q47871792-829D2A9E-D9DD-448B-8093-93C0688117AF

Q47871792-99E3899D-8F58-4989-8EC0-F4C7898625B9

Q47871792-B65092C1-807B-413A-BAF3-5B34D7808FDB

P2860

Q47871792-0063B558-3B53-4B19-B5D4-05378BD066D7

Q47871792-0110674B-4A4A-43A1-8C68-E49F1E67DC70

Q47871792-0C0094AF-376A-4488-8C37-27302E25E011

Q47871792-0C6E7DE1-02A2-49AE-810F-FAB0517C52DD

Q47871792-1083E0ED-942D-4FB4-A61D-E703AB653B31

Q47871792-20CD24BC-1D9C-467E-8E77-3196E918AAF0

Q47871792-29710332-6F3F-4029-8A32-B9ACF04683F2

Q47871792-351674C2-EF16-4A25-ADA4-CBD4B7E80BFE

Q47871792-3FF613E5-C857-45B0-B5F6-5CF9B6A37693

Q47871792-45D31826-7CE2-49D9-AE53-2FD436E902DB

P304

Q47871792-58BB7D1D-8272-42E3-B5C7-BC21DA8E2B37

P31

Q47871792-4738106B-D863-43BF-B0C0-574FC40A8D7A

P356

Q47871792-325A9AF4-E59E-4D4F-A333-1D4648282998

P433

Q47871792-F4576C6F-0AD3-4CA0-9DA2-542D5DDF3691

P478

Q47871792-10661513-2E6B-4A3E-BEFC-B224F8005E36

P577

Q47871792-D791CDE3-4A61-4473-AF5D-85910D6114F8

P698

Q47871792-9F76CCAC-775D-426F-B6B0-E5B957399B3D

P921

Q47871792-9BBA92D8-D40C-49E7-9507-4D74739EFBA2

Q47871792-A869D37E-5112-4D31-B360-AC96913F506B

Q47871792-B169B557-7192-4039-8E1C-5939D827D5FB

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Dapagliflozin in patients with ...... icacy and safety over 2 years.

@en

P2093

Dapagliflozin 006 Study Group

http://www.w3.org/2001/XMLSchema#string

J P H Wilding

http://www.w3.org/2001/XMLSchema#string

J Sugg

http://www.w3.org/2001/XMLSchema#string

K Rohwedder

http://www.w3.org/2001/XMLSchema#string

S Parikh

http://www.w3.org/2001/XMLSchema#string

V Woo

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Active sugar transport in health and disease

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

10-year follow-up of intensive glucose control in type 2 diabetes

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.

Combining insulin and oral agents.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

P304

124-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12187

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23911013

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes